Juventas Therapeutics Reports One Year Data From Phase I Heart Failure ... Sacramento Bee Juventas recently presented the 12-month results from its Phase I heart failure trial at the 7th International Conference on Cell Therapy for Cardiovascular Disease. The 17-person, open-label, dose-escalation study targeted New York Heart Association ... |
